

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/500,911
371(c) Date	July 8, 2004
I.A. Filing Date	January 9, 2003
First Named Inventor	Masakuni NODA
Art Unit	1636
Examiner Name	Daniel M. SULLIVAN
Attorney Docket Number	10577.0002-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials*	Cite No.	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code Number Kind Code (if known)				
		WO 01/40460 A1	06-07-2001	Glaxo Group Limited		

NONPATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
		NAKAMURA et al., 2001, "Inhibition of Progression of Renal Interstitial Disorder by Introduction of Egr-1 DNA Enzyme Using Electroporation," Nihon Kanzo Gakkaishi, Vol. 43, No. 3, page 189, O-142.	YES
		SOLOW et al., 1999, "Angiotensin II Inhibits Insulin-Induced agr-1 Expression in Mesangial Cells," Archives of Biochemistry and Biophysics, Vol. 370, No. 2, pages 308-313.	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.